MAP2K1 is altered in 1.05% of malignant solid tumor patients with MAP2K1 Mutation present in 0.93% of all malignant solid tumor patients [4].

MAP2K1 Mutation is an inclusion criterion in 19 clinical trials for malignant solid tumor, of which 16 are open and 3 are closed. Of the trials that contain MAP2K1 Mutation and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (6 open) [5].

MAP2K1 is altered in 0.97% of non-small cell lung carcinoma patients with MAP2K1 Mutation present in 0.85% of all non-small cell lung carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K1 Mutation and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

MAP2K1 is altered in 5.66% of melanoma patients with MAP2K1 Mutation present in 5.43% of all melanoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain MAP2K1 Mutation and melanoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

MAP2K1 is altered in 2.17% of non-hodgkin lymphoma patients with MAP2K1 Mutation present in 2.04% of all non-hodgkin lymphoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K1 Mutation and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

MAP2K1 is altered in 12.3% of histiocytic and dendritic cell neoplasm patients with MAP2K1 Mutation present in 12.3% of all histiocytic and dendritic cell neoplasm patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K1 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

MAP2K1 is altered in 1.77% of colorectal carcinoma patients with MAP2K1 Mutation present in 1.57% of all colorectal carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.95% of glioma patients with MAP2K1 Mutation present in 0.84% of all glioma patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 Mutation and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K1 is altered in 0.78% of low grade glioma patients with MAP2K1 Mutation present in 0.78% of all low grade glioma patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.41% of thyroid gland carcinoma patients with MAP2K1 Mutation present in 0.41% of all thyroid gland carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K1 is altered in 0.51% of ovarian carcinoma patients with MAP2K1 Mutation present in 0.38% of all ovarian carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 7.63% of cutaneous melanoma patients with MAP2K1 Mutation present in 7.21% of all cutaneous melanoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 4.6% of ganglioglioma patients with MAP2K1 Mutation present in 3.45% of all ganglioglioma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 3.61% of neuronal and mixed neuronal-glial tumors patients with MAP2K1 Mutation present in 3.01% of all neuronal and mixed neuronal-glial tumors patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 1.43% of endometrial carcinoma patients with MAP2K1 Mutation present in 1.39% of all endometrial carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 1.04% of cancer patients with MAP2K1 Mutation present in 0.92% of all cancer patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains MAP2K1 Mutation and cancer as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MAP2K1 is altered in 1.13% of esophageal carcinoma patients with MAP2K1 Mutation present in 0.91% of all esophageal carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 0.97% of diffuse glioma patients with MAP2K1 Mutation present in 0.86% of all diffuse glioma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.97% of gastric carcinoma patients with MAP2K1 Mutation present in 0.85% of all gastric carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 0.9% of astrocytic tumor patients with MAP2K1 Mutation present in 0.78% of all astrocytic tumor patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.62% of mucosal melanoma patients with MAP2K1 Mutation present in 0.62% of all mucosal melanoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 is altered in 0.61% of pilocytic astrocytoma patients with MAP2K1 Mutation present in 0.61% of all pilocytic astrocytoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.59% of squamous cell lung carcinoma patients with MAP2K1 Mutation present in 0.59% of all squamous cell lung carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.53% of hepatocellular carcinoma patients with MAP2K1 Mutation present in 0.53% of all hepatocellular carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 is altered in 0.8% of cholangiocarcinoma patients with MAP2K1 Mutation present in 0.5% of all cholangiocarcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 0.47% of multiple myeloma patients with MAP2K1 Mutation present in 0.47% of all multiple myeloma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 0.58% of breast carcinoma patients with MAP2K1 Mutation present in 0.4% of all breast carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.43% of renal cell carcinoma patients with MAP2K1 Mutation present in 0.36% of all renal cell carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.22% of pancreatic adenocarcinoma patients with MAP2K1 Mutation present in 0.22% of all pancreatic adenocarcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K1 is altered in 0.21% of pancreatic carcinoma patients with MAP2K1 Mutation present in 0.21% of all pancreatic carcinoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 is altered in 0.2% of soft tissue sarcoma patients with MAP2K1 Mutation present in 0.15% of all soft tissue sarcoma patients [4].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K1 Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].